Table 2 Treatment-related NCI CTCAE Version 3.0 Grade 3 or 4 treatment-emergent adverse events
System organ class, n (%) | huKS-IL2 dosing cohort, mg/m2 | Total (n = 27) | ||||
|---|---|---|---|---|---|---|
0.5 | 1.0 | 2.0 | 3.0 | 4.0 | ||
(n = 3) | (n = 4) | (n = 7) | (n = 6) | (n = 7) | ||
Any treatment-related TEAE of NCI CTCAE Grade 3 or 4 | 2 (67) | 0 | 2 (29) | 2 (33) | 5 (71) | 11 (41) |
Blood/lymphatic system disorders | ||||||
Lymphopenia | 1 (33) | 0 | 1 (14) | 2 (33) | 1 (14) | 5 (19) |
Anemia | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
Neutropenia | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
Thrombocytopenia | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
WBC count decreased | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
Investigations | ||||||
Blood phosphorus equivalents increased | 0 | 0 | 0 | 0 | 1(14) | 1 (4) |
GGT increased | 0 | 0 | 0 | 1 (17) | 0 | 1 (4) |
Gastrointestinal disorders | ||||||
Ascites | 1 (33) | 0 | 0 | 0 | 0 | 1 (4) |
Nausea | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
Vomiting | 0 | 0 | 0 | 0 | 1 (14) | 1 (4) |
Metabolism/nutrition disorders | ||||||
Hypophosphatemia | 0 | 0 | 1 (14) | 0 | 1 (14) | 2 (7) |
Respiratory/thoracic/mediastinal disorders | ||||||
Dyspnea | 0 | 0 | 0 | 1 (17) | 0 | 1 (4) |
Bronchospasm | 0 | 0 | 0 | 1 (17) | 0 | 1 (4) |
Hypoxia | 0 | 0 | 1 (14) | 0 | 0 | 1 (4) |